Verona Pharma plc (NASDAQ:VRNA – Get Free Report)’s stock price traded up 5.3% on Monday . The company traded as high as $59.74 and last traded at $60.32. 939,785 shares changed hands during trading, ...

Verona Pharma (NASDAQ:VRNA)'s stock has reached an unprecedented peak, setting an all-time high at $56.49. This milestone underscores a remarkable period of growth for the $4.49 billion ...

Venezia and Verona were still looking for their first win of the year after the relegation- threatened clubs drew 1-1 in Serie A on Monday.

(IN BRIEF) EQT Real Estate has acquired a high-quality logistics portfolio of 12 fully-let properties in Milan and Verona for approximately EUR 230 million. The 265,000-square-meter portfolio is ...

EQT Real Estate has acquired a high-quality logistics portfolio of 12 fully-let properties in Milan and Verona for approximately EUR 230 million. T ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Verona Pharma (NASDAQ:VRNA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 price target ...

H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares.

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...